Cardiomyocytes Market Segmentation:
Type Segment Analysis
The human iPSC-derived cardiomyocytes segment is predicted to account for 60% share of the cardiomyocytes market by 2035. The segment growth can be attributed to the rising prevalence of cardiovascular diseases, such as coronary heart disease, stroke, hypertension, and congestive heart failure. According to the data published by the World Health Organization cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Cardiomyocytes produced from induced pluripotent stem cells (iPSC) can improve the precision, efficacy, and accuracy of identifying cardiovascular damage hazards in drugs as well as non-pharmaceutical methods. Hence, increasing the demand for human iPSC-derived cardiomyocytes in the cardiomyocytes market.
Application Segment Analysis
Cardiac safety and toxicity segmented in cardiomyocytes market is estimated to gain a significant share during the forecast period. The segment growth can be attributed to the global rise in cardiotoxicity brought on by an increased prevalence of cancer. Cardiotoxicity is the term for heart damage caused by several cancer medications or treatments and results in cardiac diseases including but not limited to arrhythmia, myocardial infarction, and myocardial hypertrophy. Research by the World Cancer Research Fund Internation shows that there were an estimated 18.1 million cancer cases around the world in 2020. Thus showing significant growth in the cardiomyocyte market in the forecast period.
Our in-depth analysis of the Cardiomyocytes market includes the following segments:
|
Type |
|
|
Application |
|
|
End-Users |
|
